Mga Batayang Estadistika
| LEI | 5493003J2SQF7YM0BK11 |
| CIK | 1684693 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sol-Gel Technologies Ltd.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 4, 2025 |
Sol-Gel Announces Health Canada Approval of EPSOLAY® Exhibit 99.1 Sol-Gel Announces Health Canada Approval of EPSOLAY® NESS ZIONA, Israel, September 4, 2025 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, a Phase-1b, double blinded clinical trial of SGT-210 (erlot |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal ex |
|
| August 15, 2025 |
As filed with the Securities and Exchange Commission on August 15, 2025 As filed with the Securities and Exchange Commission on August 15, 2025 Registration No. |
|
| August 15, 2025 |
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Exhibit 99.1 Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates • Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026 • Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease is ongoing • Sol-Gel and Mayne Pharma Announce the Purchas |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execu |
|
| August 15, 2025 |
Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Balance Sheets F-2 Statements of Operations F-3 Statements of Changes in Shareholders' Equity F-4 - F-5 Statements of C |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executiv |
|
| May 23, 2025 |
Sol-Gel Technologies Ltd. 656,000 ORDINARY SHARES Filed pursuant to Rule 424(b)(3) SEC File No. 333-270478 PROSPECTUS SUPPLEMENT NO.2 (to Prospectus dated April 29, 2025) Sol-Gel Technologies Ltd. 656,000 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of May 5, 2023 (as supplemented or amended from time to time, the “Prospectus”) (Registra |
|
| May 23, 2025 |
Sol-Gel Reports First Quarter 2025 Results EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sol-Gel Reports First Quarter 2025 Results NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025 Total revenue in the first |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executiv |
|
| May 8, 2025 |
Sol-Gel Technologies Ltd. 656,000 ORDINARY SHARES Filed pursuant to Rule 424(b)(3) SEC File No. 333-270478 PROSPECTUS SUPPLEMENT NO.1 (to Prospectus dated April 29, 2025) Sol-Gel Technologies Ltd. 656,000 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of May 5, 2023 (as supplemented or amended from time to time, the “Prospectus”) (Registra |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| May 6, 2025 |
May 6, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: Sol-Gel Technologies Ltd. Registration Statement on Form F-3 Filed April 29, 2025 File No. 333-286822 (the “Registration Statement”) Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of Regulation C promulgated und |
|
| May 5, 2025 |
Sol-Gel Announces Reverse Share Split Exhibit 99.1 Sol-Gel Announces Reverse Share Split NESS ZIONA, Israel – May 1, 2025 – Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”), at the ratio of 10-for-1, such that each ten (10 |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executiv |
|
| April 29, 2025 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sol-Gel Technologies Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U. |
|
| April 29, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Form Type Sol-Gel Technologies Ltd. |
|
| April 29, 2025 |
Exhibit 4.17 CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Execution Copy TERMINATION AGREEMENT This Termination Agreement (this “Agreement”) is effective as of April 17, 2025 (the “Effective Date”) and is entered into by and between Galderma Holdi |
|
| April 29, 2025 |
Exhibit 4.20 CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. TERMINATION AGREEMENT This Termination Agreement ("Agreement") is entered into as of August 15, 2024 ("Effective Date"), between Padagis Israel Pharmaceuticals Ltd, a limited liability comp |
|
| April 29, 2025 |
Exhibit 4.28 CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Execution Version PRODUCT PURCHASE AGREEMENT BY AND BETWEEN MAYNE PHARMA LLC AND SOL-GEL TECHNOLOGIES LTD. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II ASSIGNMENTS AND LICENSES |
|
| April 29, 2025 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sol-Gel Technologies Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U. |
|
| April 29, 2025 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002 I, Eyal Ben-Or, certify that: 1. I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light o |
|
| April 29, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Sol-Gel Technologies Ltd. |
|
| April 29, 2025 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Moshe Arkin, certify that: 1. I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light o |
|
| April 29, 2025 |
Exhibit 4.27 CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Execution Version As amended on June 2, 2024 ASSET PURCHASE AGREEMENT by and among SOL-GEL TECHNOLOGIES LTD. AND SHENZHEN BEIMEI PHARMACEUTICAL CO., LTD. DATED AS OF MAY 15, 2024 TABLE OF C |
|
| April 29, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-223915 and 333-270477) and Form F-3 (No. 333-264190) of Sol-Gel Technologies Ltd. of our report dated April 29, 2025 relating to the financial statements, which appears in this Form 20-F. Tel-Aviv, Israel /s/ Kesselman & Kess |
|
| April 29, 2025 |
As filed with the Securities and Exchange Commission on April 29, 2025 As filed with the Securities and Exchange Commission on April 29, 2025 Registration No. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| April 29, 2025 |
Registration No. As filed with the Securities and Exchange Commission on April 29, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sol-Gel Technologies Ltd. (Exact name of registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation or organization) Not Applicable (I |
|
| April 29, 2025 |
As filed with the Securities and Exchange Commission on April 29, 2025 As filed with the Securities and Exchange Commission on April 29, 2025 Registration No. |
|
| April 29, 2025 |
Sol-Gel Technologies Ltd. Insider Trading Compliance Policy Exhibit 11.1 Sol-Gel Technologies Ltd. Insider Trading Compliance Policy This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by the Company to prevent |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execut |
|
| April 17, 2025 |
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. Exhibit 99.1 Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. • Sol-Gel to receive $16 million during 2025 • Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial • SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execut |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| February 18, 2025 |
Exhibit 99.1 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel +972-8-931-3433 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 1, 2025 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend a Special Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 9:00 a.m. Easter |
|
| February 18, 2025 |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. 7 GOLDA MEIR ST., WEIZMANN SCIENCE PARK NESS ZIONA, 7403650, ISRAEL VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Daylight Time on March 31, 2025. Have your proxy card in hand when you access the web site and follow |
|
| November 20, 2024 |
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement Exhibit 99.1 Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement NESS ZIONA, Israel, November 20, 2024 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approv |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| November 15, 2024 |
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates Exhibit 99.1 Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates • Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholders • Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated • SGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov |
|
| November 15, 2024 |
Filed pursuant to Rule 424(b)(3) SEC File No. 333-270478 PROSPECTUS SUPPLEMENT NO.4 (to Prospectus dated April 1, 2024) Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of May 5, 2023 (as supplemented or amended from time to time, the “Prospectus”) (Registr |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| November 14, 2024 |
SLGL / Sol-Gel Technologies Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk2432318.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* Sol-Gel Technologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.1 per share (Title of Class of Securities) M8694L103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) C |
|
| November 14, 2024 |
SLGL / Sol-Gel Technologies Ltd. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-slgl093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sol-Gel Technologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.1 per share (Title of Class of Securities) M8694L103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 6-K 1 zk2432214.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel ( |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal ex |
|
| September 25, 2024 |
Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. 7 GOLDA MEIR ST., WEIZMANN SCIENCE PARK NESS ZIONA, 7403650, ISRAEL VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Standard Time on November 3, 2024. Have your proxy card in hand when you access the web site and follo |
|
| September 25, 2024 |
Exhibit 99.1 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel +972-8-931-3433 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 4, 2024 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend a Special Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 9:00 a.m. Eas |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execu |
|
| August 19, 2024 |
SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Balance Sheets F - 2 Statements of Operations F - 3 Statements of Changes in Shareholders' Equity F - 4 - F - 5 Stateme |
|
| August 19, 2024 |
Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES Filed pursuant to Rule 424(b)(3) SEC File No. 333-270478 PROSPECTUS SUPPLEMENT NO.3 (to Prospectus dated April 1, 2024) Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of May 5, 2023 (as supplemented or amended from time to time, the “Prospectus”) (Registr |
|
| August 19, 2024 |
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates Exhibit 99.1 Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates • Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026 • Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 • SGT- |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| August 16, 2024 |
SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Balance Sheets F - 2 Statements of Operations F - 3 Statements of Changes in Shareholders' Equity F - 4 - F - 5 Stateme |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execu |
|
| August 16, 2024 |
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates Exhibit 99.1 Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates • Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026 • Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 • SGT- |
|
| July 25, 2024 |
Exhibit 99.1 SOL-GEL ANNOUNCES THE SIGNING OF SIX EXCLUSIVE LICENSE AGREEMENTS TO COMMERCIALIZE TWYNEO® AND EPSOLAY® IN EUROPE AND SOUTH AFRICA Sol-Gel to receive upfront and regulatory milestone payments totaling in up to low 7-digit USD and either fixed transfer sale price or low double-digit royalties from net sales; payments are backed by commitments to minimum annual sales NESS ZIONA, Israel, |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executi |
|
| July 22, 2024 |
Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES Filed pursuant to Rule 424(b)(3) SEC File No. 333-270478 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated April 1, 2024) Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of May 5, 2023 (as supplemented or amended from time to time, the “Prospectus”) (Regist |
|
| July 22, 2024 |
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 27, 2024 Exhibit 99.2 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 27, 2024 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend an Annual Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 9:00 a.m. Eastern Standard Time (4:00 p.m. Israel time) on Tuesday, August 27, 2024, at the offices of Latham & Watkins, 1271 |
|
| July 22, 2024 |
Exhibit 99.3 SOL-GEL TECHNOLOGIES LTD. 7 GOLDA MEIR ST., WEIZMANN SCIENCE PARK NESS ZIONA, 7403650, ISRAEL VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on August 26, 2024. Have your proxy card in hand when you access the web site and follow the inst |
|
| July 22, 2024 |
Sol-Gel Technologies Announces Management Realignment Exhibit 99.1 Sol-Gel Technologies Announces Management Realignment NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWY |
|
| July 15, 2024 |
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 27, 2024 Exhibit 99.2 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 27, 2024 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend an Annual Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 9:00 a.m. Eastern Standard Time (4:00 p.m. Israel time) on Tuesday, August 27, 2024, at the offices of Latham & Watkins, 1271 |
|
| July 15, 2024 |
Exhibit 99.3 SOL-GEL TECHNOLOGIES LTD. 7 GOLDA MEIR ST., WEIZMANN SCIENCE PARK NESS ZIONA, 7403650, ISRAEL VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on August 26, 2024. Have your proxy card in hand when you access the web site and follow the inst |
|
| July 15, 2024 |
Sol-Gel Technologies Announces Management Realignment Exhibit 99.1 Sol-Gel Technologies Announces Management Realignment NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWY |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executi |
|
| May 28, 2024 |
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice Exhibit 99.1 Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, T |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executiv |
|
| May 20, 2024 |
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates Exhibit 99.1 Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates • Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. • Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $115 million. • Sol-Gel recen |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executiv |
|
| May 20, 2024 |
Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES Filed pursuant to Rule 424(b)(3) SEC File No. 333-270478 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated April 1, 2024) Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of May 5, 2023 (as supplemented or amended from time to time, the “Prospectus”) (Regist |
|
| May 16, 2024 |
Exhibit 99.1 Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel Sol-Gel to receive a total consideration of up to US$15 million, out of which US$10 million will be paid as upfront and regulatory milestones NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) – Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executiv |
|
| April 8, 2024 |
SLGL / Sol-Gel Technologies Ltd. / Arkin Moshe - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES ACT OF 1934 (Amendment No. 4) Sol-Gel Technologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.1 per share M8694L103 (Title of class of securities) (CUSIP number) M. Arkin Dermatology Ltd. 6 HaChoshlim St., Bldg. C, Herzliya 46724, Israel Attn: Moshe Arkin Telephone: 972-9-7883333 with a copy to: |
|
| April 4, 2024 |
Filed Pursuant to Rule 424(b)(3) Filed Pursuant to Rule 424(b)(3) Registration No. 333- 270478 Prospectus Sol-Gel Technologies Ltd. 6,560,000 Ordinary Shares This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to 6,560,000 of our ordinary shares, par value NIS 0.1 per share. These 6,560,000 ordinary shares consist of: ● 2,560,000 ordinary shares, or the Investor Warr |
|
| April 1, 2024 |
Exhibit 99.1 Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream Patent challenge initiated by Arcutis Biotherapeutics NESS ZIONA, Israel, April 1 2024 (GLOBE NEWSWIRE) – Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execut |
|
| March 20, 2024 |
As filed with the Securities and Exchange Commission on March 20, 2024 As filed with the Securities and Exchange Commission on March 20, 2024 Registration No. |
|
| March 13, 2024 |
Exhibit 4.22 CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Execution Version LICENSE AGREEMENT BY AND BETWEEN SEARCHLIGHT PHARMA INC. AND SOL-GEL TECHNOLOGIES LTD. TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS 1 ARTICLE II. LICENSES 8 ARTICLE III. |
|
| March 13, 2024 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sol-Gel Technologies Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U. |
|
| March 13, 2024 |
Sol-Gel Technologies Ltd. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 Sol-Gel Technologies Ltd. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Sol-Gel Technologies Ltd. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject t |
|
| March 13, 2024 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 2.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 This section summarizes certain information regarding the ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”) of Sol-Gel Technologies Ltd. (the “Company”). The Ordinary Shares constitute the only class of the Company’s securities that is registered under Section 12 of the |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 13, 2024 |
Exhibit 2.3 REGISTRATION RIGHTS AGREEMENT AGREEMENT dated as of March 30, 2023 (this “Agreement”) among Sol-Gel Technologies Ltd., a company incorporated under the laws of the Israel (the “Company”), and M. Arkin Dermatology Ltd. In consideration of the mutual promises made herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties h |
|
| March 13, 2024 |
Exhibit 4.23 CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Execution Version LICENSE AGREEMENT BY AND BETWEEN SEARCHLIGHT PHARMA INC. AND SOL-GEL TECHNOLOGIES LTD. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II LICENSES 9 ARTICLE III GOV |
|
| March 13, 2024 |
Re: Extension of the lease periods Exhibit 4.13 Dr. Moshe Eliash Barrister-at-law, Advocate and Notary 2 Hasoreg St., POB 433 Telephone 651681, 6054281 Faximilia 6254282 Jerusalem 91003 [email protected] Sunday, 25 June 2023 To: Sol-Gel Golda Meir 7 Ness Ziona Re: Extension of the lease periods The owners of the property agree to extend all the lease periods in accordance with all the lease agreements, so that the aforementioned |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execut |
|
| March 13, 2024 |
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments Exhibit 99.1 Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments • An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 • Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatolo |
|
| March 13, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-223915 and 333-270477) and Form F-3 (No. 333-264190) of Sol-Gel Technologies Ltd. of our report dated March 13, 2024, relating to the financial statements, which appears in this Form 20-F. Tel-Aviv, Israel /s/Kesselman & Kess |
|
| March 13, 2024 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sol-Gel Technologies Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U. |
|
| March 13, 2024 |
Exhibit 4.3 COMPENSATION POLICY SOL-GEL TECHNOLOGIES LTD. Compensation Policy for Executive Officers and Directors ADOPTED: July 26 2023 Table of Contents Page A. Overview and Objectives A-3 B. Base Salary and Benefits A-5 C. Cash Bonuses (Excluding Directors) A-6 D. Equity-Based Compensation A-8 E. Retirement and Termination of Service Arrangements (Excluding Directors) A-9 F. Exemption, Indemnif |
|
| March 13, 2024 |
AMENDED AND RESTATED ARTICLES OF ASSOCIATION LAST AMENDED ON: JUNE 22, 2022 TABLE OF CONTENTS Exhibit 1.2 SOL-GEL TECHNOLOGIES LTD. AMENDED AND RESTATED ARTICLES OF ASSOCIATION LAST AMENDED ON: JUNE 22, 2022 TABLE OF CONTENTS INTERPRETATION 1 NAME OF THE COMPANY 2 OBJECTIVES 2 PUBLIC COMPANY 2 LIMITED LIABILITY 2 CAPITAL, SHARES AND RIGHTS 3 REGISTERED HOLDER 4 TRANSFER OF SHARES 4 TRANSMISSION OF SHARES 5 CALLS ON SHARES 5 ALTERATIONS OF THE REGISTERED SHARE CAPITAL 6 MODIFICATION OF CLAS |
|
| March 13, 2024 |
CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002 I, Gilad Mamlok, certify that: 1. I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light |
|
| March 13, 2024 |
CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alon Seri-Levy, certify that: 1. I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| March 6, 2024 |
2023 PFIC Annual Information Statement Sol-Gel Technologies Ltd. Exhibit 99.1 IMPORTANT NOTICE TO SHAREHOLDERS WHO ARE UNITED STATES PERSONS March 6, 2024 This statement is provided for shareholders of Sol-Gel Technologies Ltd. (the “Company”) who are United States persons (“U.S. Shareholders”) for purposes of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). We believe that the Company may meet the Code definition of a passive foreign investment |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execut |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| February 14, 2024 |
SLGL / Sol-Gel Technologies Ltd. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2024 |
SLGL / Sol-Gel Technologies Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* Sol-Gel Technologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.1 per share (Title of Class of Securities) M8694L103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| January 31, 2024 |
SC 13G 1 zk2430847.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. ) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Under the Securities Exchange Act of 1934 Sol-Gel Technologies Ltd. (Name of Issuer) Ordinary Shares (Title of |
|
| January 23, 2024 |
Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. 7 GOLDA MEIR ST., WEIZMANN SCIENCE PARK NESS ZIONA, 7403650, ISRAEL VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Standard Time on February 27, 2024. Have your proxy card in hand when you access the web site and foll |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exec |
|
| January 23, 2024 |
Exhibit 99.1 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel +972-8-931-3433 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 28, 2024 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend a Special Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 9:00 a.m. Ea |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exec |
|
| January 17, 2024 |
Exhibit 99.1 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel +972-8-931-3433 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 28, 2024 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend a Special Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 9:00 a.m. Ea |
|
| November 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| November 30, 2023 |
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study Exhibit 99.1 Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study • SGT-610 has “Orphan Drug” designation status in the U.S. and E.U. and “Breakthrough Therapy” designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs in Gorlin syndrome • Sol-Gel to host a virtual Key Opinion Leader event to discuss the Gorlin syndrome patient experienc |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| November 9, 2023 |
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update • Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 • Gorlin Syndrome KOL event to be held on December 6, 2023 • Sol-Gel maintains cash runway into the second half of 2025 NESS ZIONA, Israel, November 9, 2023 - Sol-G |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| November 9, 2023 |
Filed pursuant to Rule 424(b)(3) SEC File No. 333-270478 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated May 5, 2023) Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of May 5, 2023 (as supplemented or amended from time to time, the “Prospectus”) (Registra |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of August 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execu |
|
| August 10, 2023 |
Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES Filed pursant to Rule 424(b)(3) SEC File No. 333-270478 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated May 5, 2023) Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of May 5, 2023 (as supplemented or amended from time to time, the “Prospectus”) (Registrat |
|
| August 10, 2023 |
Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Balance Sheets F-2 Statements of Operations F-3 Statements of Changes in Shareholders' Equity F-4 - F-5 Statements of C |
|
| August 10, 2023 |
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update • Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 • Sol-Gel’s recently announced agreement with Searchlight Pharma will provide up to $11 million in upfront payments and regulatory and sales milestones for both TW |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) For the month of July 2023 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check mar |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of July 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execu |
|
| June 21, 2023 |
Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. 7 GOLDA MEIR ST., WEIZMANN SCIENCE PARK NESS ZIONA, 7403650, ISRAEL VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on July 25, 2023. Have your proxy card in hand when you access the web site and follow the instru |
|
| June 21, 2023 |
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 26, 2023 Exhibit 99.1 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 26, 2023 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend an Annual Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 4:00 p.m. (Israel time) on Wednesday, July 26, 2023, at our offices at 7 Golda Meir St., Weizmann Science Park, Ness Ziona, Isra |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executi |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executi |
|
| June 14, 2023 |
Exhibit 99.1 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel +972-8-931-3433 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON July 26, 2023 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend the Annual Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 4:00 p.m. (Israe |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of June 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executi |
|
| June 6, 2023 |
Exhibit 99.1 Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada • Sol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined, plus additional royalties ranging from low double-digits to high-teens • Non-dilutive capital strengthens Sol-Gel’s balance sheet • Searchlight Pharma antici |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of May 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executiv |
|
| May 12, 2023 |
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update • Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 • Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 • Phase 1 trial for SGT-210 |
|
| May 12, 2023 |
Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES Filed pursuant to Rule 424(b)(3) SEC File No. 333-270478 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated May 5, 2023) Sol-Gel Technologies Ltd. 6,560,000 ORDINARY SHARES This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of May 5, 2023 (as supplemented or amended from time to time, the “Prospectus”) (Registra |
|
| May 3, 2023 |
Sol-Gel Technologies Ltd. 7 Golda Meir St., Weizmann Science Park Ness Ziona, 7403648, Israel Sol-Gel Technologies Ltd. 7 Golda Meir St., Weizmann Science Park Ness Ziona, 7403648, Israel May 3, 2023 Via EDGAR Transmission Tyler Howes Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Sol-Gel Technologies Ltd. Registration Statement on Form F-1 Filed March 10, 2023 Registration No. 333-270478 Dear Mr. Howes: In accordance with R |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execut |
|
| March 20, 2023 |
SLGL / Sol-Gel Technologies Ltd / Arkin Moshe - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES ACT OF 1934 (Amendment No. 3) Sol-Gel Technologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.1 per share M8694L103 (Title of class of securities) (CUSIP number) M. Arkin Dermatology Ltd. 6 HaChoshlim St., Bldg. C, Herzliya 46724, Israel Attn: Moshe Arkin Telephone: 972-9-7883333 with a copy to: |
|
| March 10, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 Form Type Sol-Gel Technologies Ltd. |
|
| March 10, 2023 |
Certification by Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 13.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sol-Gel Technologies Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U. |
|
| March 10, 2023 |
Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002 I, Gilad Mamlok, certify that: 1. I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light |
|
| March 10, 2023 |
Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alon Seri-Levy, certify that: 1. I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 10, 2023 |
Exhibit 4.23 CERTAIN IDENTIFIED INFORMATION MARKED [***] HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Execution Version ASSET PURCHASE AGREEMENT By and Between SOL-GEL TECHNOLOGIES LTD. and PELLEPHARM, INC. January 23, 2023 Table of Contents Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 PURCHASE A |
|
| March 10, 2023 |
Amended and Restated Articles of Association. Exhibit 1.2 SOL-GEL TECHNOLOGIES LTD. AMENDED AND RESTATED ARTICLES OF ASSOCIATION LAST AMENDED ON: JUNE 22, 2022 TABLE OF CONTENTS INTERPRETATION 1 NAME OF THE COMPANY 2 OBJECTIVES 2 PUBLIC COMPANY 2 LIMITED LIABILITY 2 CAPITAL, SHARES AND RIGHTS 3 REGISTERED HOLDER 4 TRANSFER OF SHARES 4 TRANSMISSION OF SHARES 5 CALLS ON SHARES 5 ALTERATIONS OF THE REGISTERED SHARE CAPITAL 6 MODIFICATION OF CLAS |
|
| March 10, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-223915) and Form F-3 (No. 333-264190) of Sol-Gel Technologies Ltd. of our report dated March 10, 2023, relating to the financial statements, which appears in this Form 20-F. Tel-Aviv, Israel /s/Kesselman & Kesselman March 10, |
|
| March 10, 2023 |
Exhibit 2.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 This section summarizes certain information regarding the ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”) of Sol-Gel Technologies Ltd. (the “Company”). The Ordinary Shares constitute the only class of the Company’s securities that is registered under Section 12 of the |
|
| March 10, 2023 |
EX-4.3 4 exhibit4-3.htm EXHIBIT 4.3 Exhibit 4.3 COMPENSATION POLICY SOL-GEL TECHNOLOGIES LTD. Compensation Policy for Executive Officers and Directors ADOPTED: June 22, 2022 Table of Contents Page A. Overview and Objectives A- 3 B. Base Salary and Benefits A- 5 C. Cash Bonuses (Excluding Directors) A-6 D. Equity-Based Compensation A- 8 E. Retirement and Termination of Service Arrangements (Excludi |
|
| March 10, 2023 |
As filed with the Securities and Exchange Commission on March 10, 2023 As filed with the Securities and Exchange Commission on March 10, 2023 Registration No. |
|
| March 10, 2023 |
Certification by Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 13.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sol-Gel Technologies Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U. |
|
| March 10, 2023 |
Registration No. As filed with the Securities and Exchange Commission on March 10, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sol-Gel Technologies Ltd. (Exact name of registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation or organization) Not Applicable (I |
|
| March 10, 2023 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 Form Type Sol-Gel Technologies Ltd. (Exact Name of Registrant as Specified in its Charter Table 1: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2014 Shar |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of March 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execut |
|
| March 1, 2023 |
Exhibit 99.1 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel +972-8-931-3433 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 30, 2023 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend a Special Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 4:00 p.m. (Isra |
|
| March 1, 2023 |
Exhibit 99.2 Important Notice Regarding the Availability of Proxy Materials for the Special Meeting: The Notice and Proxy Statement is available at www.proxyvote.com. V00166-S63073 SOL-GEL TECHNOLOGIES LTD. Proxy for Special Meeting of Shareholders on March 30, 2023 Solicited on Behalf of the Board of Directors The undersigned hereby appoints Alon Seri-Levy and Gilad Mamlok, and each of them, with |
|
| February 21, 2023 |
Exhibit 99.1: Notice of Special Meeting of Shareholders scheduled for March 30, 2023. Exhibit 99.1 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel +972-8-931-3433 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 30, 2023 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend a Special Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 4:00 p.m. (Isra |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 6-K/A 1 zk2329278.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Isra |
|
| February 14, 2023 |
SLGL / Sol-Gel Technologies Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk2329230.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* Sol-Gel Technologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.1 per share (Title of Class of Securities) M8694L103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Ch |
|
| February 13, 2023 |
Exhibit 99.1 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel +972-8-931-3433 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 23, 2023 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend a Special Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 4:00 p.m. (Isra |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 6-K 1 zk2329196.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel ( |
|
| February 2, 2023 |
Exhibit 99.1 NASDAQ: SLGL This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the benefits we expect to receive under our |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of February 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| January 31, 2023 |
FORM OF ORDINARY SHARE PURCHASE WARRANT Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 31, 2023 |
Exhibit 10.2 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Subscription”) is dated as of January 27, 2023, by and between Sol-Gel Technologies Ltd., a company limited by shares organized under the laws of the State of Israel (the “Company”), and M. Arkin Dermatology Ltd., an Israeli company (the “Investor”). RECITALS A. The Company is contemplating (i) the issuance and sale of ordinary |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exec |
|
| January 31, 2023 |
Exhibit 5.1 Tel Aviv, January 30, 2023 Sol-Gel Technologies Ltd. 7 Golda Meir St. Weizman Science Park Ness Ziona, 7403650 Israel Re: Sol-Gel Technologies Ltd. Ladies and Gentlemen: We have acted as Israeli counsel for Sol-Gel Technologies Ltd., a company organized under the laws of Israel (the “Company”), in connection with (a) the issuance and sale by the Company to the Purchasers (as defined be |
|
| January 31, 2023 |
Exhibit 99.1 Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings NESS ZIONA, Israel, January 27, 2023 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products that were launched in the U.S. by partner Galderma du |
|
| January 31, 2023 |
FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 27, 2023, between Sol-Gel Technologies Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers” |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exec |
|
| January 27, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-264190 PROSPECTUS SUPPLEMENT (To Prospectus dated April 13, 2022) 2,560,000 Ordinary Shares Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 2,560,000 of our ordinary shares in a registered direct offering directly to an institutional and accredited investor, at a price of $5.00 per ordinary share, for gro |
|
| January 27, 2023 |
Exhibit 99.1 Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million − Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA − Phase 3 study expected to initiate in the second ha |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of January 2023 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant’s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exec |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. ) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Under the Securities Exchange Act of 1934 Sol-Gel Technologies Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M8694L103 |
|
| November 21, 2022 |
Exhibit 99.1 Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update ? Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribers ? Sol-Gel?s cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, November 10, 2022 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2022 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of October 2022 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exec |
|
| October 3, 2022 |
Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development NESS ZIONA, Israel, October 3, 2022?Sol-Gel Technologies, Ltd. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of August 2022 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check m |
|
| August 4, 2022 |
Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Balance Sheets F-2 Statements of Operations F-3 Statements of Changes in Shareholders' Equity F-4 - F-5 Statements of C |
|
| August 4, 2022 |
Exhibit 99.1 Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? Prescription volumes to date indicate strong uptake, similar to successful dermatology launches ? Sol-Gel receives $3.5 million milestone payment from commercial partner Galderma Holding SA (?Galderma?) for FDA approval of EPSOLAY ? Sol-Gel?s cash runway expected to extend through the en |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of June 2022 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check mar |
|
| June 8, 2022 |
Exhibit 99.1 NASDAQ: SLGL This presentation contains ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the timing of future clinical trials, our expe |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of June 2022 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executi |
|
| May 23, 2022 |
Exhibit 99.1 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 23, 2022 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend an Annual Meeting of Shareholders (the ?Meeting?) of Sol-Gel Technologies Ltd. (the ?Company?) to be held at 4:00 p.m. (Israel time) on Thursday, June 23, 2022, at our offices at 7 Golda Meir St., Weizmann Science Park, Ness Ziona, Israel. |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of May 2022 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check ma |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of May 2022 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check mark |
|
| May 19, 2022 |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. 7 GOLDA MEIR ST., WEIZMANN SCIENCE PARK NESS ZIONA, 7403650, ISRAEL VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on June 22, 2022. Follow the instructions to obtain your records and to create an electronic voti |
|
| May 19, 2022 |
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 23, 2022 Exhibit 99.1 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 23, 2022 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend an Annual Meeting of Shareholders (the ?Meeting?) of Sol-Gel Technologies Ltd. (the ?Company?) to be held at 4:00 p.m. (Israel time) on Thursday, June 23, 2022, at our offices at 7 Golda Meir St., Weizmann Science Park, Ness Ziona, Israel. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of May 2022 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executiv |
|
| May 16, 2022 |
Exhibit 99.1 NASDAQ: SLGL This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the commercial launch of TWYNEO, the regulator |
|
| May 13, 2022 |
Exhibit 99.1 Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update ? FDA approval for EPSOLAY? (benzoyl peroxide, cream, 5%) represents Sol-Gel?s second approved product within less than a year; EPSOLAY is patent protected until 2040 ? Partner Galderma to launch two products in the U.S. this quarter: TWYNEO launched in the U.S. market in April for the topi |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of May 2022 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check mark |
|
| May 12, 2022 |
Exhibit 99.1 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel +972-8-931-3433 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 23, 2022 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend an Annual Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 4:00 p.m. (Israel |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of May 2022 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check mark |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of April 2022 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execut |
|
| April 19, 2022 |
Exhibit 5.1 April 19, 2022 Sol-Gel Technologies Ltd. 7 Golda Meir Street, Weizmann Science Park, Ness Ziona, 7403650, Israel Re: Sol-Gel Technologies Ltd. Ladies and Gentlemen: We have acted as Israeli counsel for Sol-Gel Technologies Ltd., a company organized under the laws of Israel (the ?Company?), in connection with the issuance and sale by the Company of ordinary shares of the Company, par va |
|
| April 19, 2022 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM April 19, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Sol-Gel Technologies Ltd., a company organized under the laws of the State of Israel (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agen |
|
| April 19, 2022 |
Up to $23,000,000 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-264190 PROSPECTUS SUPPLEMENT (To Prospectus dated April 13, 2022) Up to $23,000,000 Ordinary Shares We have entered into an Open Market Sale AgreementSM, or the Sale Agreement, with Jefferies LLC, or Jefferies, dated April 19, 2022, relating to our ordinary shares, par value NIS 0.1 per share, offered by this prospectus supplement and the accom |
|
| April 14, 2022 |
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 19, 2022 Exhibit 99.1 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 19, 2022 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend an Annual Meeting of Shareholders (the ?Meeting?) of Sol-Gel Technologies Ltd. (the ?Company?) to be held at 4:00 p.m. (Israel time) on Thursday, May 19, 2022, at our offices at 7 Golda Meir St., Weizmann Science Park, Ness Ziona, Israel. T |
|
| April 14, 2022 |
Exhibit 99.2 Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice and Proxy Statement is available at www.proxyvote.com. SOL-GEL TECHNOLOGIES LTD. Proxy for Annual Meeting of Shareholders on May 19, 2022 Solicited on Behalf of the Board of Directors The undersigned hereby appoints Alon Seri-Levy and Gilad Mamlok, and each of them, with full power of sub |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of April 2022 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check ma |
|
| April 11, 2022 |
Sol-Gel Technologies Ltd. 7 Gold Meir St., Weizmann Science Park Ness Ziona, 7403650, Israel Sol-Gel Technologies Ltd. 7 Gold Meir St., Weizmann Science Park Ness Ziona, 7403650, Israel April 11, 2022 Via EDGAR Transmission Tim Buchmiller Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Sol-Gel Technologies Ltd. Registration Statement on Form F-3 Filed April 7, 2022 Registration No. 333-264190 Dear Mr. Buchmiller: In accordan |
|
| April 8, 2022 |
Exhibit 99.1 SOL-GEL TECHNOLOGIES LTD. 7 Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650, Israel +972-8-931-3433 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 19, 2022 Dear Sol-Gel Technologies Ltd. Shareholders: We cordially invite you to attend an Annual Meeting of Shareholders, or the Meeting, of Sol-Gel Technologies Ltd., or the Company, to be held at 4:00 p.m. (Israel |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of April 2022 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check ma |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 toFORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 toFORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| April 7, 2022 |
Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES‑OXLEY ACT OF 2002 I, Gilad Mamlok, certify that: 1. I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light |
|
| April 7, 2022 |
As filed with the Securities and Exchange Commission on April 7, 2022 As filed with the Securities and Exchange Commission on April 7, 2022 Registration No. |
|
| April 7, 2022 |
Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alon Seri-Levy, certify that: 1. I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| April 7, 2022 |
Certification by Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 13.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sol-Gel Technologies Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U. |
|
| April 7, 2022 |
Certification by Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 13.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sol-Gel Technologies Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U. |
|
| April 7, 2022 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-223915) and Form F-3 (No. 333-230564) of Sol-Gel Technologies Ltd. of our report dated April 4, 2022 relating to the financial statements, which appears in this Amendment No. 1 to Form 20-F. Tel-Aviv, Israel /s/Kesselman & Kes |
|
| April 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Sol-Gel Technologies Inc. |
|
| April 4, 2022 |
Exhibit 4.21 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Contract Manufacturing Agreement DOUGLAS MANUFACTURING LIMITED SOL-GEL TECHNOLOGIES LIMITED GALDERMA SA May 28, 2021 AGREEMENT DETAILS Parties DOUGLAS MANUFACTURING LIMITED (?Douglas?) SOL-GEL TECHN |
|
| April 4, 2022 |
Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES?OXLEY ACT OF 2002 I, Gilad Mamlok, certify that: 1. I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light |
|
| April 4, 2022 |
License Agreement between Sol-Gel Technologies Ltd. and Galderma Holding SA, dated June 21, 2021. Exhibit 4.20 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Copy LICENSE AGREEMENT BY AND BETWEEN GALDERMA HOLDING SA AND SOL-GEL TECHNOLOGIES LTD. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II LICENSES 9 ARTICLE III GOVERNANCE 11 ARTIC |
|
| April 4, 2022 |
Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Exhibit 12.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Alon Seri-Levy, certify that: 1. I have reviewed this annual report on Form 20-F of Sol-Gel Technologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| April 4, 2022 |
Certification by Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 13.2 CERTIFICATION BY CHIEF FINANCIAL OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sol-Gel Technologies Ltd. (the ?Company?) on Form 20-F for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), the undersigned officer of the Company certifies, pursuant to 18 U. |
|
| April 4, 2022 |
Exhibit 4.22 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. TERMINATION AGREEMENT This Termination Agreement ("Agreement") is entered into as of November 3, 2021 ("Effective Date"), between Padagis Israel Pharmaceuticals Ltd, a limited liability company orga |
|
| April 4, 2022 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-223915) and Form F-3 (No. 333-230564) of Sol-Gel Technologies Ltd. of our report dated April 4, 2022 relating to the financial statements, which appears in this Form 20-F. Tel-Aviv, Israel /s/Kesselman & Kesselman April 4, 202 |
|
| April 4, 2022 |
Certification by Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Exhibit 13.1 CERTIFICATION BY CHIEF EXECUTIVE OFFICER PURSUAN TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Sol-Gel Technologies Ltd. (the ?Company?) on Form 20-F for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), the undersigned officer of the Company certifies, pursuant to 18 U. |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| April 4, 2022 |
License Agreement between Sol-Gel Technologies Ltd. and Galderma Holding SA, dated June 21, 2021. Exhibit 4.19 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Execution Copy LICENSE AGREEMENT BY AND BETWEEN GALDERMA HOLDING SA AND SOL-GEL TECHNOLOGIES LTD. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II LICENSES 8 ARTICLE III GOVERNANCE 10 ARTIC |
|
| April 4, 2022 |
Exhibit 4.23 CERTAIN INFORMATION IDENTIFIED BY BRACKETED ASTERISKS ([* * *]) HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. TERMINATION AGREEMENT ([***]) This Termination Agreement ("Agreement") is entered into as of November 3, 2021 ("Effective Date"), between Padagis Israel Pharmaceuticals Ltd, a limited liability comp |
|
| April 4, 2022 |
Exhibit 4.3 COMPENSATION POLICY SOL-GEL TECHNOLOGIES LTD. Compensation Policy for Executive Officers and Directors Adopted October 2, 2017, as amended March 22, 2021 Table of Contents Page A. Overview and Objectives A- 3 B. Base Salary and Benefits A- 4 C. Cash Bonuses (Excluding Directors) A-6 D. Equity-Based Compensation A- 7 E. Retirement and Termination of Service Arrangements (Excluding Direc |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of March 2022 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check ma |
|
| March 30, 2022 |
Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments Exhibit 99.1 Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments ? Galderma launched TWYNEO? at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially available in Spring 2022. ? 2021 revenue of $31.3 million ? Sol-Gel to receive $21.5 million over 24 months in exchange for the transfer of its ri |
|
| February 7, 2022 |
SLGL / Sol-Gel Technologies Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Sol-Gel Technologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.1 per share (Title of Class of Securities) M8694L103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 7, 2022 |
Exhibit 1 [Unofficial Translation] December 12, 2019 Powers of Signature in The Phoenix Holdings Ltd. |
|
| February 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. ) (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Under the Securities Exchange Act of 1934 Sol-Gel Technologies Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M8694L103 |
|
| January 5, 2022 |
Exhibit 99.1 NASDAQ: SLGL This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ?may,? ?will,? ?should,? ?expect,? ?plan,? ?anticipate,? ?could,? ?future,? ?ou |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of January 2022 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exec |
|
| December 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of December 2021 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| December 21, 2021 |
Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY® EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY® - FDA informs Sol-Gel that it intends to conduct a pre-approval inspection of the production site for EPSOLAY during the week of February 14th, 2022 NESS ZIONA, Israel, December 21, 2021 - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focuse |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of November 2021 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal exe |
|
| November 16, 2021 |
Exhibit 99.1 NASDAQ: SLGL This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ?may,? ?will,? ?should,? ?expect,? ?plan,? ?anticipate,? ?could,? ?future,? ?ou |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of November 2021 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check |
|
| November 12, 2021 |
Exhibit 99.1 Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments ? Sol-Gel attains a profitable quarter, reporting total revenues of $8.8 million, net income of $1.3 million and EPS of $0.06 ? Recently obtained FDA approval of TWYNEO? triggers a $3.5 million milestone payment from Galderma, and, together with the $4.0 million down payment |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of November 2021 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check |
|
| November 8, 2021 |
Exhibit 99.1 Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million - Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs - Sol-Gel to retain two generic programs encompassing four high-value generic drug candidates - Sol-Gel?s cash runway expect |
|
| September 9, 2021 |
Exhibit 99.1 NASDAQ: SLGL September 2021 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ?may,? ?will,? ?should,? ?expect,? ?p |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of September 2021 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal ex |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of August 2021 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execu |
|
| August 4, 2021 |
Exhibit 99.2 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 SOL-GEL TECHNOLOGIES LTD. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2021 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Balance Sheets F?-?2 Statements of Operations F?-?3 Statements of Changes in Shareholders' Equity F?-?4?-?F?-?5 Stateme |
|
| August 4, 2021 |
Exhibit 99.1 Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments ? Recently obtained FDA approval of TWYNEO? triggers milestone payment from Galderma ? Exclusive license agreements with Galderma for U.S. commercialization of EPSOLAY? and TWYNEO ? Sol-Gel advancing its early-stage pipeline in plaque psoriasis, palmoplantar keratoderma and |
|
| August 4, 2021 |
Exhibit 99.1 NASDAQ: SLGL August 2021 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ?may,? ?will,? ?should,? ?expect,? ?plan |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of August 2021 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal execu |
|
| July 27, 2021 |
Sol-Gel Technologies Announces FDA Approval of TWYNEO® Exhibit 99.1 Sol-Gel Technologies Announces FDA Approval of TWYNEO? ? TWYNEO?, a once-daily cream treatment for acne vulgaris, is the first FDA?approved fixed?dose combination of tretinoin and benzoyl peroxide ? TWYNEO utilizes Sol-Gel?s proprietary microencapsulation technology and is patent protected until 2038 ? Under a previously announced license, Sol?Gel to receive regulatory milestone payme |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of July 2021 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check mar |
|
| July 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of July 2021 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executi |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) For the month of May 2021 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executive offices) Indicate by check mark |
|
| June 28, 2021 |
Exhibit 99.2 Sol-Gel Announces Pipeline Update and Future Development Plans ? Sol-Gel investigational SGT-510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal model ? Sol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients compared to the brand expected to be launched ? Our |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of June 2021 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executi |
|
| June 28, 2021 |
Exhibit 99.1 Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY? and TWYNEO? in the United States - Upfront and approval payments of up to $15 million - Tiered royalties ranging from mid- to high-teen percentage of net sales - Sol-Gel option to regain commercialization rights 5 years following first commercialization NESS ZIONA, Israel / LAUSANNE, Sw |
|
| June 28, 2021 |
Exhibit 99.1 NASDAQ: SLGL June 2021 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ?may,? ?will,? ?should,? ?expect,? ?plan,? |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the month of June 2021 Commission File Number 001-38367 SOL-GEL TECHNOLOGIES LTD. (Translation of registrant?s name into English) 7 Golda Meir Street Ness Ziona 7403650, Israel (Address of principal executi |
|
| June 22, 2021 |
Exhibit 99.1 NASDAQ: SLGL June 2021 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ?may,? ?will,? ?should,? ?expect,? ?plan,? |
|
| June 1, 2021 |
Exhibit 99.2 Important Notice Regarding the Availability of Proxy Materials for the Annual General Meeting: The Notice and Proxy Statement is available at www.proxyvote.com. D55708-P59126 SOL-GEL TECHNOLOGIES LTD. Proxy for Annual General Meeting of Shareholders on July 8, 2021 Solicited on Behalf of the Board of Directors The undersigned hereby appoints Alon Seri-Levy and Gilad Mamlok, and each o |
|
| June 1, 2021 |
Exhibit 99.1 NASDAQ: SLGL June 2021 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ?may,? ?will,? ?should,? ?expect,? ?plan,? |
